INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman

On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) saw its market capitalization decrease by over $2.2 billion after revealing the results of its NHS-Galleri Trial. The announcement surprised investors and led to substantial financial losses. In response, a securities class action lawsuit has been initiated, offering investors with substantial losses the chance to participate as lead plaintiffs. This legal action underscores the impact of the trial results on investor confidence and the company's market valuation. The lawsuit is led by Hagens Berman, a law firm specializing in securities litigation. The event highlights the importance of clinical trial outcomes in the biotech sector and their immediate effect on stock performance. However, the broader market implications remain uncertain, and this development primarily affects current shareholders and potential class members.